| Name | Title | Contact Details |
|---|
Southcoast Medical Group, P C is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Savannah, GA. To find more information about Southcoast Medical Group, P C, please visit www.southcoastmedical.com
OmnisSYS is a Greenville, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
B C Decker Inc. is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Central Peninsula Hospital, Inc., an acute care hospital, provides patient and resident centered care services serving the Central Peninsula area. It offers emergency care, anesthesia, emergency medicine, family medicine, ENT, general surgery, internal medicine, neurology, OB/GYN, ophthalmology, orthopedics, pathology, pediatrics, podiatry, psychiatry, and radiology services; and behavioral health services that include depression screenings, substance abuse treatment, and substance abuse treatment services. The company also provides imaging services that include diagnostic imaging, digital mammography examinations, computer axial tomography procedures, ultrasound/sonography, nuclear medicine, and magnetic resonance imaging; physical, occupational, speech, and massage therapy services; outpatient weight loss, walking and exercise programs, cardiac rehabilitation, and diabetes management services; and diabetes education services. In addition, it offers family birth center services; laboratory services that include chemistry, hematology, transfusion medicine, serology, urinalysis, microbiology, and molecular biology testing; various treatments to outpatients include chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement; and sleep center services. Central Peninsula Hospital, Inc. was formerly known as Central Peninsula General Hospital, Inc. The company was founded in 1971 and is based in Soldotna, Alaska with practices in Kenai and Soldotna, Alaska.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.